Pharmaceutical composition for synergistically inhibiting liver cancer sorafenib drug resistance and application thereof

A technology of synergistic inhibition and composition, applied in the field of pharmaceutical composition for synergistic inhibition of sorafenib drug resistance in liver cancer

Pending Publication Date: 2020-09-08
SHANGHAI CHANGHAI HOSPITAL
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report about the combined application of melittin and bufalin to improve the curative effect of sorafenib-resistant liver cancer and play a synergistic anti-sorafenib-resistant liver cancer effect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for synergistically inhibiting liver cancer sorafenib drug resistance and application thereof
  • Pharmaceutical composition for synergistically inhibiting liver cancer sorafenib drug resistance and application thereof
  • Pharmaceutical composition for synergistically inhibiting liver cancer sorafenib drug resistance and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: The killing effect of melittin and bufalin single drug on SMMC-7721-R

[0028] cell line

[0029] Sorafenib-acquired drug-resistant human liver cancer cell line: SMMC-7721-R, which was constructed and preserved in the Institute of Tumor Research of Traditional Chinese Medicine of the People's Liberation Army (Liu Dong, Fan Yifu, Li Jun, Cheng Binbin, Lin Wanfu, Li Xiaoyan, DuJuan* , Ling Changquan*. Inhibition of cFLIP overcomes acquired resistance to Sorafenib via reducing ER stress-related autophagy in hepatocellular carcinoma. Oncol Rep 2018; 40(4):2206-14.).

[0030] 1. Plating: take normal growing SMMC-7721-R cells, digest with trypsin, centrifuge (1000rpm, 5min), count under a microscope with a cell counting plate; dilute the cell concentration to 5.0×10 4 cells / mL of cell suspension, which was added to a 96-well plate (100 μL / well) and placed in a cell culture incubator (37°C, 5% CO 2 ), incubated for 12h.

[0031] 2. Dosing: 12 hours after the cell...

Embodiment 2

[0037]Embodiment 2: The killing effect of melittin and bufalin combined on SMMC-7721-R

[0038] The difference between melittin and bufalin at 48h and 72h is relatively small (the IC of melittin and bufalin at 48h 50 0.38±0.13μmol / L, 1.64±0.54μmol / L, respectively). Therefore, in the next step, we choose the action time of the two drugs to be 48h. We set 5 concentrations of the two drugs respectively (the set concentration is IC 50 and two concentrations above and below). The concentration gradient of bufalin is: 0.1μmol / L, 0.2μmol / L, 0.4μmol / L, 0.8μmol / L, 1.6μmol / L; the concentration gradient of melittin is: 0.5μmol / L, 1μmol / L , 2 μmol / L, 4 μmol / L, 8 μmol / L; paired in pairs to form 25 groups, which were tested for CCK-8 activity.

[0039] 1. As shown in Table 1, two groups were combined, a total of 25 groups; a negative control group (only containing cells, no drug treatment) and a blank group (only containing complete medium) were set at the same time, with 6 replicate we...

Embodiment 3

[0045] Example 3: Effects of melittin and bufalin combined on the apoptosis of SMMC-7721-R

[0046] The comprehensive index analysis has verified that 1.0 μmol / L melittin + 0.2 μmol / L bufolin is the optimal synergistic drug ratio. In order to verify this result, we further used flow cytometry to detect the combined use of melittin / bufalin and the two drugs alone (the single drug concentration of melittin was 2.0 μmol / L, and the concentration of bufalin single drug was 0.4 μmol / L). ) on the apoptosis of liver cancer cells. Melittin and bufalin were combined to act on SMMC-7721-R cells for 48 hours, and cell apoptosis was detected after Annexin V-APC / PI double staining.

[0047] 1. Plating and dosing: Plate SMMC-7721 and SMMC-7721-R on a 12-well plate; after 12 hours of wall attachment, add DMEM containing 0 μmol / L, 5 μmol / L, 10 μmol / L and 20 μmol / L Sorafenib respectively Above 12-well plate culture medium.

[0048] 2. Aspirate the cell culture solution into the centrifuge tu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines, in particular to application of melittin and bufalin combination in preparation of a medicine for treating liver cancer, a pharmaceutical composition for synergistically inhibiting liver cancer sorafenib resistance and application of the pharmaceutical composition. The composition has the advantages that the melittin and the bufalin can play a goodanti-liver cancer role through different mechanisms, the anti-liver cancer curative effect can be improved through combined application of the melittin and the bufalin, the synergistic anti-liver cancer sorafenib drug resistance role is played, and the using effect is better than that of a single drug.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for synergistically inhibiting drug resistance of liver cancer sorafenib and application thereof. Background technique [0002] Primary liver cancer is one of the major cancers that has attracted worldwide attention, ranking third in the global tumor-related deaths. In my country, the incidence of primary liver cancer ranks fourth among all types of tumors, and the death rate ranks third. The number of new cases and deaths both account for more than half of the global total, making China a major liver cancer country. At present, the treatment methods for liver cancer include liver transplantation, liver cancer resection, hepatic arterial chemoembolization, stereotactic radiotherapy, radiofrequency ablation, and molecular targeted therapy. Most patients with liver cancer are already in the middle and advanced stages when they are diagnosed, and surgical resec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K31/585A61P35/00
CPCA61K31/585A61K38/1767A61P35/00A61K2300/00
Inventor 黄念凌昌全王丽娜杜娟何煜宇干正王曼阮亦贺海威
Owner SHANGHAI CHANGHAI HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap